{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:26:00Z","timestamp":1793676360221,"version":"4.5.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00259-026-08101-z","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:30:55Z","timestamp":1785810655000},"page":"8129-8138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical impact of 18F-FES PET\/CT-detected ER-positive conversion in metastatic breast cancer with ER-negative primary tumors"],"prefix":"10.1007","volume":"53","author":[{"given":"Sanxing","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6195-9942","authenticated-orcid":false,"given":"Zhongyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"8101_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74:477\u201395. https:\/\/doi.org\/10.3322\/caac.21863.","journal-title":"CA Cancer J Clin"},{"key":"8101_CR2","doi-asserted-by":"publisher","first-page":"e1918160","DOI":"10.1001\/jamanetworkopen.2019.18160","volume":"3","author":"Y Li","year":"2020","unstructured":"Li Y, Yang D, Yin X, Zhang X, Huang J, Wu Y, et al. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer. JAMA Netw Open. 2020;3:e1918160. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.18160.","journal-title":"JAMA Netw Open"},{"key":"8101_CR3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ijc.33227","volume":"148","author":"ZB Yi","year":"2021","unstructured":"Yi ZB, Yu P, Zhang S, Wang WN, Han YQ, Ouyang QC, et al. Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study. Int J Cancer. 2021;148:692\u2013701. https:\/\/doi.org\/10.1002\/ijc.33227.","journal-title":"Int J Cancer"},{"key":"8101_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13058-016-0725-1","volume":"18","author":"EH Allott","year":"2016","unstructured":"Allott EH, Geradts J, Sun X, Cohen SM, Zirpoli GR, Khoury T, et al. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification. Breast Cancer Res. 2016;18:68. https:\/\/doi.org\/10.1186\/s13058-016-0725-1.","journal-title":"Breast Cancer Res"},{"issue":"Suppl 2","key":"8101_CR5","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1038\/modpathol.2008.34","volume":"21","author":"AM Gown","year":"2008","unstructured":"Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21(Suppl 2):S8\u201315. https:\/\/doi.org\/10.1038\/modpathol.2008.34.","journal-title":"Mod Pathol"},{"key":"8101_CR6","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2967\/jnumed.117.198846","volume":"59","author":"HH Nienhuis","year":"2018","unstructured":"Nienhuis HH, van Kruchten M, Elias SG, Glaudemans A, de Vries EFJ, Bongaerts AHH, et al. (18)F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. J Nucl Med. 2018;59:1212\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.198846.","journal-title":"J Nucl Med"},{"key":"8101_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11307-013-0699-7","volume":"16","author":"LM Peterson","year":"2014","unstructured":"Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, et al. A phase 2 study of 16\u03b1-[18F]-fluoro-17\u03b2-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Mol Imaging Biol. 2014;16:431\u201340. https:\/\/doi.org\/10.1007\/s11307-013-0699-7.","journal-title":"Mol Imaging Biol"},{"key":"8101_CR8","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.2967\/jnumed.120.256826","volume":"62","author":"J Boers","year":"2021","unstructured":"Boers J, Loudini N, Brunsch CL, Koza SA, de Vries EFJ, Glaudemans A, et al. Value of (18)F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study. J Nucl Med. 2021;62:1214\u201320. https:\/\/doi.org\/10.2967\/jnumed.120.256826.","journal-title":"J Nucl Med"},{"key":"8101_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2967\/jnumed.125.270763","volume":"67","author":"JM Specht","year":"2026","unstructured":"Specht JM, van Geel JJL, Song S, Liu C, Hippe DS, DiGregorio NA, et al. The Role of Estrogen Receptor-Targeted PET with 16\u03b1-(18)F-Fluoro-17\u03b2-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis. J Nucl Med. 2026;67:36\u201342. https:\/\/doi.org\/10.2967\/jnumed.125.270763.","journal-title":"J Nucl Med"},{"key":"8101_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.annonc.2024.02.007","volume":"35","author":"A Gennari","year":"2024","unstructured":"Gennari A, Brain E, De Censi A, Nanni O, Wuerstlein R, Frassoldati A, et al. Early prediction of endocrine responsiveness in ER+\/HER2-negative metastatic breast cancer (MBC): pilot study with (18)F-fluoroestradiol ((18)F-FES) CT\/PET. Ann Oncol. 2024;35:549\u201358. https:\/\/doi.org\/10.1016\/j.annonc.2024.02.007.","journal-title":"Ann Oncol"},{"key":"8101_CR11","doi-asserted-by":"publisher","first-page":"109821","DOI":"10.1016\/j.ejrad.2021.109821","volume":"141","author":"G Bottoni","year":"2021","unstructured":"Bottoni G, Piccardo A, Fiz F, Siri G, Matteucci F, Rocca A, et al. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET\/CT and [18F]Fluorodeoxyglucose PET\/CT. Eur J Radiol. 2021;141:109821. https:\/\/doi.org\/10.1016\/j.ejrad.2021.109821.","journal-title":"Eur J Radiol"},{"key":"8101_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/rlu.0000000000001587","volume":"42","author":"Z Yang","year":"2017","unstructured":"Yang Z, Sun Y, Xu X, Zhang Y, Zhang J, Xue J, et al. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET\/CT. Clin Nucl Med. 2017;42:421\u20137. https:\/\/doi.org\/10.1097\/rlu.0000000000001587.","journal-title":"Clin Nucl Med"},{"key":"8101_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00259-017-3740-2","volume":"44","author":"N Aide","year":"2017","unstructured":"Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM\/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017;44:17\u201331. https:\/\/doi.org\/10.1007\/s00259-017-3740-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8101_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2967\/jnumed.123.266938","volume":"65","author":"D Mankoff","year":"2024","unstructured":"Mankoff D, Balogov\u00e1 S, Dunnwald L, Dehdashti F, DeVries E, Evangelista L, et al. Summary: SNMMI Procedure Standard\/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16\u03b1-[(18)F]Fluoro-17\u03b2-Estradiol PET. J Nucl Med. 2024;65:221\u20133. https:\/\/doi.org\/10.2967\/jnumed.123.266938.","journal-title":"J Nucl Med"},{"key":"8101_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41523-021-00252-6","volume":"7","author":"T Grinda","year":"2021","unstructured":"Grinda T, Joyon N, Lusque A, Lef\u00e8vre S, Arnould L, Penault-Llorca F, et al. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. NPJ Breast Cancer. 2021;7:41. https:\/\/doi.org\/10.1038\/s41523-021-00252-6.","journal-title":"NPJ Breast Cancer"},{"key":"8101_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2967\/jnumed.111.092734","volume":"53","author":"M van Kruchten","year":"2012","unstructured":"van Kruchten M, Glaudemans AW, de Vries EF, Beets-Tan RG, Schr\u00f6der CP, Dierckx RA, et al. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med. 2012;53:182\u201390. https:\/\/doi.org\/10.2967\/jnumed.111.092734.","journal-title":"J Nucl Med"},{"key":"8101_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/jnci\/djx273","volume":"110","author":"W Schrijver","year":"2018","unstructured":"Schrijver W, Suijkerbuijk KPM, van Gils CH, van der Wall E, Moelans CB, van Diest PJ. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. J Natl Cancer Inst. 2018;110:568\u201380. https:\/\/doi.org\/10.1093\/jnci\/djx273.","journal-title":"J Natl Cancer Inst"},{"key":"8101_CR18","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/s1470-2045(18)30936-7","volume":"20","author":"SY Chae","year":"2019","unstructured":"Chae SY, Ahn SH, Kim SB, Han S, Lee SH, Oh SJ, et al. Diagnostic accuracy and safety of 16\u03b1-[(18)F]fluoro-17\u03b2-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. Lancet Oncol. 2019;20:546\u201355. https:\/\/doi.org\/10.1016\/s1470-2045(18)30936-7.","journal-title":"Lancet Oncol"},{"key":"8101_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13058-022-01555-7","volume":"24","author":"C Liu","year":"2022","unstructured":"Liu C, Hu S, Xu X, Zhang Y, Wang B, Song S, et al. Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment. Breast Cancer Res. 2022;24:57. https:\/\/doi.org\/10.1186\/s13058-022-01555-7.","journal-title":"Breast Cancer Res"},{"key":"8101_CR20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s12149-023-01871-8","volume":"37","author":"C Liu","year":"2023","unstructured":"Liu C, Ma G, Zhang J, Cheng J, Yang Z, Song S. (18)F-FES and (18)F-FDG PET\/CT imaging as a predictive biomarkers for metastatic breast cancer patients undergoing cyclin-dependent 4\/6 kinase inhibitors with endocrine treatment. Ann Nucl Med. 2023;37:675\u201384. https:\/\/doi.org\/10.1007\/s12149-023-01871-8.","journal-title":"Ann Nucl Med"},{"key":"8101_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature14583","volume":"523","author":"H Mohammed","year":"2015","unstructured":"Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, et al. Progesterone receptor modulates ER\u03b1 action in breast cancer. Nature. 2015;523:313\u20137. https:\/\/doi.org\/10.1038\/nature14583.","journal-title":"Nature"},{"key":"8101_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2147\/dddt.S336643","volume":"16","author":"Z Li","year":"2022","unstructured":"Li Z, Wei H, Li S, Wu P, Mao X. The Role of Progesterone Receptors in Breast Cancer. Drug Des Devel Ther. 2022;16:305\u201314. https:\/\/doi.org\/10.2147\/dddt.S336643.","journal-title":"Drug Des Devel Ther"},{"key":"8101_CR23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.2967\/jnumed.124.269163","volume":"66","author":"AS Parihar","year":"2025","unstructured":"Parihar AS, Vaz S, Sutcliffe S, Pant N, Schoones JW, Ulaner GA. (18)F-Fluoroestradiol PET\/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Metaanalysis. J Nucl Med. 2025;66:692\u20139. https:\/\/doi.org\/10.2967\/jnumed.124.269163.","journal-title":"J Nucl Med"},{"key":"8101_CR24","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.2967\/jnumed.124.267913","volume":"65","author":"J Ryu","year":"2024","unstructured":"Ryu J, Hyung J, Han S, Jeong JH, Lee SB, Yoo TR, et al. Impact of (18)F-FES PET\/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer. J Nucl Med. 2024;65:1689\u201394. https:\/\/doi.org\/10.2967\/jnumed.124.267913.","journal-title":"J Nucl Med"},{"key":"8101_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1158\/1078-0432.Ccr-16-0362","volume":"23","author":"BF Kurland","year":"2017","unstructured":"Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, et al. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Clin Cancer Res. 2017;23:407\u201315. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-0362.","journal-title":"Clin Cancer Res"},{"key":"8101_CR26","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1002\/cncr.27518","volume":"118","author":"LD Hoefnagel","year":"2012","unstructured":"Hoefnagel LD, Moelans CB, Meijer SL, van Slooten HJ, Wesseling P, Wesseling J, et al. Prognostic value of estrogen receptor \u03b1 and progesterone receptor conversion in distant breast cancer metastases. Cancer. 2012;118:4929\u201335. https:\/\/doi.org\/10.1002\/cncr.27518.","journal-title":"Cancer"},{"key":"8101_CR27","doi-asserted-by":"publisher","first-page":"e2330330","DOI":"10.2214\/ajr.23.30330","volume":"223","author":"MF Covington","year":"2024","unstructured":"Covington MF, O\u2019Brien SR, Lawhn-Heath C, Pantel AR, Ulaner GA, Linden HM, et al. (18)F-Labeled Fluoroestradiol PET\/CT: Current Status, Gaps in Knowledge, and Controversies-AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2024;223:e2330330. https:\/\/doi.org\/10.2214\/ajr.23.30330.","journal-title":"AJR Am J Roentgenol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08101-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08101-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08101-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:29:41Z","timestamp":1793672981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08101-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["8101"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08101-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This was a retrospective observational study. The Research Ethics Committee of Fudan University Shanghai Cancer Center confirmed that this study was exempt from ethical approval.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The PET\/CT images used in this study were de-identified and did not contain any information that could identify individual patients.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived by the Research Ethics Committee of Fudan University Shanghai Cancer Center.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}